Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

NeoCOAST-2 ctDNA clearance tracks with outcomes in resectable lung cancer

NeoCOAST-2 links ctDNA clearance and pCR with longer event-free survival in resectable NSCLC, with the Dato-DXd arm showing the strongest signals.

By Dr. Revathy Mohan V.R., MBBS · Oct 26, 2026 · 5 min read

Oncology·ACC-PRO

J&J RIPTAC prostate cancer data draw strong ESMO response

Johnson & Johnson unveiled early RIPTAC data in advanced prostate cancer, with deep PSA responses and manageable toxicity…

Oct 26, 2026

Oncology·bioRxiv

Droplet Organoid Screens Expose New Cancer Vulnerabilities

Droplet-based organoid culture scaled cancer screening into nanoliter compartments, revealing drug and CRISPR vulnerabilities missed by genomics alone.

Oct 26, 2026

Oncology·STAT

AstraZeneca Oncology Portfolio Takes Center Stage at ESMO

AstraZeneca used ESMO to showcase the breadth of its oncology portfolio, with multiple presidential sessions featuring company medicines…

Oct 26, 2026

Oncology·JAMA Open

Carboplatin Shortage Policy Often Missed Intent in 7-Site Health System

During a severe carboplatin shortage, 26% of allocation decisions diverged from policy intent, with documentation gaps and site…

Oct 25, 2026

Oncology·Cancer Disc

Body Roundness Index and Cancer Risk in Postmenopausal Women

Women’s Health Initiative data examine whether body roundness index tracks cancer risk in postmenopausal women, extending obesity assessment…

Oct 25, 2026

Oncology·Nature

Multiple Myeloma Multiomic Predictors Map MRD Response After Quadruplet Therapy

Multiomic profiling of 423 newly diagnosed multiple myeloma cases linked gene expression, methylation and genomic instability to MRD…

Oct 25, 2026

Oncology·JCO

Antibody therapeutics pipeline expanded sharply in 2021

Commercial antibody development accelerated in 2021, with rapid COVID-19 authorizations, 11 first approvals in major markets, and a…

Oct 25, 2026

Oncology·FDA

FDA approves dostarlimab for dMMR rectal cancer before surgery

FDA grants accelerated approval to dostarlimab for certain locally advanced rectal cancers, potentially sparing patients chemotherapy, radiation, and…

Oct 25, 2026

Oncology·Br J Cancer

GPC3 Marks Poor Prognosis in Gastric Cancer, Study Finds

Transcriptomic and clinical analyses link GPC3 overexpression to worse gastric cancer outcomes and a putative LINC02381/miR-96-5p axis.

Oct 25, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.